Form 4: Dexcom CEO Kevin Sayer Executes Stock Transactions Following Vesting of Performance Stock Units
SEC Form 4 Filing
Dexcom's CEO, Kevin Sayer, acquired 68,503 shares of common stock through the vesting of performance stock units and subsequently sold 33,359 shares to cover tax obligations.
Summary
- Dexcom CEO Kevin Sayer acquired 68,503 shares of common stock on January 28, 2025, due to the vesting of performance stock units granted in March 2022.
- Following the vesting, Mr. Sayer sold 33,359 shares on January 29, 2025, at a price of $86.9141 per share to cover tax withholding obligations.
- The sale was not a discretionary trade but was mandated by Dexcom's equity incentive plans.
- After these transactions, Mr. Sayer directly owns 319,037 shares of Dexcom common stock.
- This total includes 109,641 unvested restricted stock units granted on various dates.
Sentiment
Score: 5
Explanation: The document reflects routine transactions related to executive compensation and does not indicate any positive or negative sentiment.
Industry Context
This is a routine transaction for a company where executives receive equity compensation. The sale of shares to cover tax obligations is a common practice.
Comparison to Industry Standards
- Many companies in the technology and healthcare sectors use stock-based compensation as part of their executive pay packages.
- The 'sell to cover' mechanism is a standard practice to manage tax liabilities associated with vesting equity.
- Comparable companies like Abbott and Medtronic also have similar stock-based compensation plans for their executives.
Stakeholder Impact
- The transactions have a minimal impact on shareholders as they are part of the standard executive compensation process.
- The sale of shares to cover tax obligations is a common practice and does not indicate any change in the company's fundamentals.
Key Dates
| Date | Description |
|---|---|
| 03/08/2022 | Performance stock units were granted to Kevin Sayer, some of which vested on January 28, 2025. |
| 03/09/2023 | Restricted stock units were granted to Kevin Sayer, vesting through March 8, 2026. |
| 03/08/2024 | Restricted stock units were granted to Kevin Sayer, vesting through March 8, 2027. |
| 01/28/2025 | Performance stock units vested, resulting in the acquisition of 68,503 shares. |
| 01/29/2025 | 33,359 shares were sold to cover tax obligations at $86.9141 per share. |
| 01/30/2025 | Form 4 filing date. |
Keywords
Dexcom, Kevin Sayer, stock transaction, performance stock units, vesting, tax withholding, equity incentive plans, restricted stock units, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.